TY - JOUR
T1 - Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe
T2 - Findings and Implications
AU - Godman, Brian
AU - Wladysiuk, Magdalene
AU - McTaggart, Stuart
AU - Kurdi, Amanj
AU - Allocati, Eleonora
AU - Jakovljevic, Mihajlo
AU - Kalemeera, Francis
AU - Hoxha, Iris
AU - Nachtnebel, Anna
AU - Sauermann, Robert
AU - Hinteregger, Manfred
AU - Marković-Peković, Vanda
AU - Tubic, Biljana
AU - Petrova, Guenka
AU - Tachkov, Konstantin
AU - Slabý, Juraj
AU - Nejezchlebova, Radka
AU - Krulichová, Iva Selke
AU - Laius, Ott
AU - Selke, Gisbert
AU - Langner, Irene
AU - Harsanyi, András
AU - Inotai, András
AU - Jakupi, Arianit
AU - Henkuzens, Svens
AU - Garuolienė, Kristina
AU - Gulbinovič, Jolanta
AU - Bonanno, Patricia Vella
AU - Rutkowski, Jakub
AU - Ingeberg, Skule
AU - Melien, Øyvind
AU - Mardare, Ileana
AU - Fürst, Jurij
AU - MacBride-Stewart, Sean
AU - Holmes, Carol
AU - Pontes, Caridad
AU - Zara, Corinne
AU - Pedrola, Marta Turu
AU - Hoffmann, Mikael
AU - Kourafalos, Vasileios
AU - Pisana, Alice
AU - Banzi, Rita
AU - Campbell, Stephen
AU - Wettermark, Bjorn
N1 - Publisher Copyright:
© 2021 Brian Godman et al.
PY - 2021
Y1 - 2021
N2 - Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results. Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.
AB - Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results. Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.
UR - http://www.scopus.com/inward/record.url?scp=85118382707&partnerID=8YFLogxK
U2 - 10.1155/2021/9996193
DO - 10.1155/2021/9996193
M3 - Article
C2 - 34676266
AN - SCOPUS:85118382707
SN - 2314-6133
VL - 2021
JO - BioMed Research International
JF - BioMed Research International
M1 - 9996193
ER -